Geron Sees Blockbuster Opportunity For Imetelstat, Eyeing Broader Market Than Reblozyl’s

 
• By Alaric DeArment
Geron announced Phase III results for imetelstat in lower-risk myelodysplastic syndrome • Source: Shutterstock

More from Anticancer

More from Therapeutic Category